

Our Ref: 401/2022

October 2022

## **Re: Your request made under the Freedom of Information Act 2000**

I am analysing the usage of new biologic medications within dermatology. Could you please tell me how many patients were treated in September 2022 (or latest available month) by the dermatology department with the following drugs:

- Abrocitinib (Cibinqo) - 0
- Baricitinib (Olmiant) - 0
- Bimekizumab (Bimzelx) - 0
- Brodalumab (Kyntheum) - 4
- Dupilumab (Dupixent) - 6
- Ixekizumab (Taltz) - 3
- Risankizumab (Skyrizi) - 0
- Guselkumab (Tremfya) - 0
- Secukinumab (Cosentyx) - 19
- Tildrakizumab (Ilumetri) - 0
- Tralokinumab (Adtralza) - 0
- Upadacitinib (Rinvoq) - 0
- Ustekinumab (Stelara) - 7